Empowering Patients, Elevating Care:
Improving Cultural Competency in Inflammatory Bowel Disease (IBD) Care

1.25 AMA PRA Credits
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures
Instructions

Program Overview

This 1.25-hour CME-certified on-demand webcast offers healthcare providers an immersive learning experience focused on closing gaps in inflammatory bowel disease (IBD) care through clinical innovation and cultural competency.

Led by expert faculty Dr. Aline Charabaty, the program explores the latest evidence-based strategies for diagnosing and managing IBD, integrating new and emerging therapies, optimizing treat-to-target approaches, and addressing the influence of social determinants of health. Dr. Charabaty highlights practical, patient-centered methods for improving outcomes across diverse populations and mitigating healthcare access and equity challenges.

Following the webcast, learners will engage with an AI-powered patient simulation included within the course. This interactive module features dynamic patient avatars that replicate complex, real-world scenarios—allowing participants to practice diagnostic reasoning, treatment selection, and culturally sensitive communication in a safe, feedback-driven environment. Real-time coaching and performance tracking reinforce learning and provide actionable insights for clinical application.

A “follow-up” case within the simulation enables learners to apply key takeaways, assess knowledge retention, and strengthen the link between education and practice.

Developed in collaboration with the Color of Gastrointestinal Illness (COGI) and regional faculty ambassadors, this program promotes practical skill-building and reflection on how culturally responsive care can enhance outcomes in IBD management.

Target Audience

The intended audience for this activity is gastroenterology fellows, gastroenterologists, internists, nurse practitioners, and physician assistants involved in the management of patients with IBD.

Supporter Acknowledgement

This educational activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Apply evidence-based diagnostic criteria to identify IBD and its complications in diverse patient populations, including atypical presentations in underserved communities.
  • Demonstrate improved competency in selecting of new and emerging IBD therapies with consideration of patient-specific factors.  
  • Outline personalized treatment plans that integrate new therapeutic options and biomarker monitoring. 
  • Describe strategies for integrating precision medicine tools into personalized IBD treatment plans. 
  • Integrate culturally competent care strategies into treat-to-target approaches to improve IBD patient outcomes including patients with social and economic barriers. 
  • Demonstrate effective communication strategies that consider diverse backgrounds, beliefs, and preferences. 

Accredited Provider

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.25 contact hours including 0.0 pharmacotherapeutic contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Faculty, Staff, and Planners’ Disclosures

Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium
The planners and managers at Iridium have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Aline J. Charabaty, MD
Associate Professor of Clinical Medicine
Clinical Director of Gastroenterology Sibley Memorial Hospital and Director of the Inflammatory Bowel Disease Center at Sibley Memorial Hospital
Washington, D.C.

Disclosures
Consulting fee: Abbvie, Eli Lilly, Janssen, Pfizer, Sanofi, Takeda 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must: 

  • Read the learning objectives and faculty disclosures Complete the pretest
  • Attend the live meeting
  • Participate in the patient simulation
  • Complete the posttest with a score of 70% or higher
  • Complete the evaluation

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

System Requirements

System requirements
This educational activity is supported by an independent educational grant from Takeda  Pharmaceuticals U.S.A., Inc.

Maximum Credit Amount: 1.25

Credit Type: ACCME, ANCC
Release: 10/31/2025
Expiration: 10/31/2026

In Partnership with: